8legs: Gilead sciences

#1 out of 1

U.S. names HIV, arthritis drugs for next Medicare price talks

The U.S. named 15 drugs for Medicare price negotiations effective in 2028, under the Inflation Reduction Act.
Biktarvy and Xeljanz are among the drugs selected for price talks, reflecting IRA goals to reduce patient costs.
The 2028 list also includes treatments administered in doctors’ offices and hospitals, such as Cosentyx and Botox.
Analysts say negotiated prices beginning in 2028 could be manageable for the industry.
CMS said the selected drugs accounted for about $27 billion in U.S. spending over the year ending Oct. 31, 2025.
The IRA has sparked court challenges from drugmakers opposing government price setting.
Analysts noted several selected medicines may lose exclusivity soon, affecting pricing dynamics.
The list includes drugs from Gilead, Lilly, AbbVie, Johnson & Johnson, Pfizer, and Bristol Myers
The selection process targeted medicines with reduced generic competition and long development times.
The government hopes negotiated prices will save billions for Medicare residents when fully implemented.
The 2028 negotiations reflect ongoing efforts to curb prescription drug costs under the IRA.

Vote 0